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T he FIRE AND ICE Trial (ClinicalTrials.gov, identifierNCT01490814) was initiated in 2012 as a multicenter,
randomized, head-to-head comparison of radiofrequency
current (RFC) and cryoballoon catheter ablation for the
treatment of patients with drug-refractory symptomatic
paroxysmal atrial fibrillation (AF). Six years on, it remains
the largest, randomized comparison of safety and efficacy
between 2 catheter ablation modalities used in the treatment
of patients with AF. This landmark trial not only established
noninferiority between cryoballoon and RFC ablation for
pulmonary vein isolation (PVI) with regard to the study’s
efficacy and safety primary end points,1 but also, it evaluated
secondary end points that were critical for a representative
study interpretation.
In congruence with our trial data presentations, Pocock and
Stone discussed characteristics of a clinical trial that should be
evaluated to ascertain clinically meaningful outcomes from
statistically positive trials.2 Specifically, their review focused
on the balanced interpretation of clinical evidence. In addition
to the magnitude of benefit, the size of the trial, the balance
between safety and efficacy, and the specificity of the results
to a select patient population, the authors discuss careful
interpretation of composite primary outcomes and the impor-
tant role secondary outcomes can play in interpreting results.2
Because thoughtful assessment of secondary end points can
reveal treatment implications that may otherwise be hidden
within the primary (often composite) trial end points, the FIRE
AND ICE Trial was predefined to evaluate secondary measures
of clinical success. These secondary end points were designed
to capture insight into the patient-felt burden of AF after
cryoballoon or RFC ablation and identified significant differ-
ences between treatment cohorts in measures of clinical
success for both patients and healthcare systems.3,4
The secondary outcomes advanced our understanding of
the patient-felt impact of AF recurrence after ablation, but
important outstanding questions remain. To identify critical
evidence gaps that need to be addressed, this review first
comprehensively summarizes the published data from the
FIRE AND ICE Trial. It then provides additional analyses to
evaluate the influence of events that occurred during the
blanking period on the overall patient burden of AF recurrence
and the impact of newly introduced technology on the trial
results. Finally, we discuss outstanding questions and antic-
ipated upcoming trials aimed at closing knowledge gaps to
ultimately guide and optimize treatment strategies across the
AF disease continuum.
What We Know From the FIRE AND ICE Trial
Primary Efficacy and Safety
The FIRE AND ICE Trial tested noninferiority between cryobal-
loon (Arctic Front or Arctic Front Advance; Medtronic, Inc) and
RFC (ThermoCool, ThermoCool SF, or ThermoCool SmartTouch;
Biosense Webster, Inc) ablation for PVI in a large, randomized
cohort of patients with drug-refractory paroxysmal AF.1 The
primary efficacy end point was assessed by way of a time-to-
first-event analysis, outside the landmark 90-day blanking
period (during which, recurrence[s] of atrial arrhythmias were
not counted against the primary end point), of the following
prespecified failure events: (1) documented recurrence of AF
>30 seconds, atrial tachycardia, or atrial flutter; (2) prescription
of antiarrhythmic drugs; and (3) repeat catheter ablation. The
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Kaplan-Meier primary efficacy event-rate estimates at
12 months after the index procedure were 34.6% in the
cryoballoon cohort and 35.9% in the RFC cohort, confirming
noninferiority between the ablation modalities (P<0.001).1
This trial also identified no difference in the primary safety
end point between treatment cohorts (P=0.24).1 Although
there was no statistical difference in the absolute number of
patients who reached the primary safety end point, there were
differences in the type of safety events that occurred in
cryoballoon- versus RFC-treated patients. Specifically, phrenic
nerve injury at discharge was reported more often in the
cryoballoon (2.7%) than in the RFC treatment cohort (0%;
P=0.001), and there was a trend for more groin site
complications in the RFC cohort than in the cryoballoon
cohort (4.3% versus 1.9%; P=0.09).1 The occurrence of atrial
flutter or atrial tachycardia after catheter ablation of AF is well
documented, and although debated, it is thought to be
created (in part) by incomplete lesions or gaps in AF ablation
lines that develop into a new substrate for a reentry circuit.5
For this reason, occurrences of atrial flutter and atrial
tachycardia were also included as a serious adverse event.
It was reported that atrial flutter and atrial tachycardia tended
to be more prevalent in the RFC cohort versus the cryoballoon
cohort (10/376 [2.7%] versus 3/374 [0.8%]; P=0.09).1 This
observation may suggest that newly arrhythmogenic tissue,
potentially driven by incomplete PVI or tissue heterogeneity,
tends to be created more frequently after an index RFC
ablation than an index cryoablation.
Secondary Outcomes
Because the FIRE AND ICE Trial was a large trial and the primary
end point hypothesis was met, it was both appropriate and
important to evaluate this data set further with respect to
secondary outcomes.2 Predefined secondary end points in the
trial were designed to compare procedure and fluoroscopy
times between the 2 cohorts as well as the patient-felt disease
burden of AF through quality of life, cardiovascular rehospital-
izations, and repeat ablations. Mean total procedure and left
atrial dwell durations were significantly shorter in the cryobal-
loon cohort, whereas mean fluoroscopy time was significantly
shorter in the RFC cohort.1 As per the Short Form 12 and the
EuroQol 5-dimension form, the treatment groups experienced
similar improvements in mental and physical measures of
quality of life by 6 months, which were maintained in both
groups throughout follow-up.3 Secondary analyses also
revealed that the cryoballoon cohort (versus RFC) had signif-
icantly fewer all-cause rehospitalizations (32.6% versus 41.5%;
P=0.01), cardiovascular rehospitalizations (23.8% versus
35.9%; P<0.01), repeat ablations (11.8% versus 17.6%;
P=0.03), and direct current cardioversion after the index
procedure (3.2% versus 6.4%; P=0.04).3
The reduced need for subsequent medical treatment after
the index ablation procedure in the cryoballoon cohort was a
clinical result illustrating the generalized impact that AF
disease burden imposes on current healthcare systems. A
trial-period economic analysis revealed lower resource use in
the cryoballoon treatment group (205 healthcare uses in 122
of 374 patients) compared with the RFC treatment group (268
healthcare uses in 154 of 376 patients).4 This reduction in
resource use was modeled to translate into significantly
reduced patient and overall healthcare expenditures across 3
distinct healthcare systems (ie, Germany, United Kingdom,
and United States).4
For Which Patients Is Catheter Ablation
Challenging?
Regardless of the catheter ablation modality, 37% (281/750) of
patients treated in the trial reached the primary efficacy end
point.1 The reasons for individual patient failure and the optimal
strategy to treat patients for whom PVI is inadequate remain
largely unknown. To inform treatment strategy, a multivariable
regression analysis was performed to identify baseline charac-
teristics that predict poor outcomes after catheter ablation of
paroxysmal AF, regardless of the treatment modality. Of 22
baseline patient characteristics, female sex was a strong,
independent predictor of the primary end point and of
cardiovascular rehospitalization.6 Baseline characteristics that
were indicative of a longer cardiac disease progress (previous
direct current cardioversion, hypertension, and longer duration
of AF) were also independently associated with poorer clinical
outcomes,6 but it is unclear how these baseline characteristics
impede clinical success. To better understand the impact of
treatment paradigms on patient outcomes, we returned to the
study data set to assess the influence of the 90-day blanking
period on patient burden of arrhythmia recurrence and to
assess the effect of technological advancement on trial results.
What We Can Still Learn: Patient-Felt Burden
of AF Disease and the Blanking Period
Time-to-first event analyses can be critical to a robust clinical
study because they are designed to restrict the influence of
oversampling bias by a few highly symptomatic subjects in a
larger patient cohort; however, themajor limitation of this clinical
study design in real-world patient application is that it fails to
reveal the sequalae a patient experiences after the clinical trial
end point. The “patient burden” of AF recurrence after an index
ablation is not limited to the first event, but rather is defined by
the summation of the number, type, and severity of events that
follow. As illustrated, a patientwithout any AF recurrence after an
index procedure is deemed a clinical trial success (Figure 1) and
DOI: 10.1161/JAHA.118.010777 Journal of the American Heart Association 2
FIRE AND ICE Contemporary Review Kuck et al
C
O
N
T
E
M
P
O
R
A
R
Y
R
E
V
IE
W
likely lives a lifestyle reflective of that freedom from atrial
arrhythmia. By comparison, both a patient with an isolated
recurrence and a patient with frequent recurrences are equally
deemed clinical trial failures by time-to-first event analysis
(Figure 1). However, in the real world, the patient with frequent
recurrences is burdened by more episodes of atrial arrhythmias
than the patient with an isolated recurrence, and, therefore, the
former patient is more likely to undergo a future cardioversion,
rehospitalization, and/or repeat ablation. Arrhythmias that lead
to emergency department triage and rehospitalization should not
be ignored (or remainuncounted) because of a time-to-first-event
clinical study design.
The distinction between “clinically free of AF” and “mean-
ingfully free of AF” is increasingly recognized,7,8 and future
studies will define patient disease burden and healthcare
burden while still collecting traditional clinical study mea-
surements of AF burden. In the FIRE AND ICE Trial, predefined
secondary outcome measurements were rigorously collected
and analyzed with the intention to explore patient and
healthcare arrhythmia burden. Although the trial was not
designed to assess AF burden (ie, the percentage of time a
patient was in AF), the predefined secondary outcomes
elucidated the impact of 2 different catheter ablation
treatments on patient-felt AF disease burden via measures
of quality of life, repeat ablations, and cardiovascular rehos-
pitalizations, which one may infer are the outcome measures
of AF disease burden.
The secondary analysis was predefined to include events
that occurred during the blanking period to capture the total
patient and healthcare burden of AF recurrence between the 2
cohorts. However, for this current review of study data,
cardiovascular rehospitalization and repeat ablations that
occurred during the 90-day blanking period were excluded to
reveal the impact of these early events on the overall
conclusions (Figure 2). This additional analysis demonstrated
that there were significantly fewer cardiovascular rehospital-
izations in the cryoballoon cohort whether or not events in the
90-day blanking period were included in the analysis (P<0.01
and P=0.02, respectively; Figure 2A). RFC catheter ablation
was associated with a significantly higher risk of
Figure 1. Clinical trial success and failure vs patient burden of atrial fibrillation (AF) recurrence. Clinical trial success is illustrated in the top
panel by the absence of AF recurrence events from the time of the index ablation through the end of the study period indicated by the vertical,
dashed line. The middle panel demonstrates a patient who reached the clinical trial end point via an isolated AF recurrence, indicated by the
single, vertical solid line within the study period. The bottom panel represents a patient who reached the clinical trial end point and subsequently
experienced multiple AF recurrence events after the initial recurrence, which is demonstrated by the collection of vertical, solid lines over time.
Critically, both patients in the middle and bottom panel initially recurred at the same time point during the clinical trial; therefore, these 2
patients are counted equally in the primary efficacy end point, although the burden of AF that followed the initial recurrence drastically differs
between the 2 patients.
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cardiovascular rehospitalization regardless of the events that
occurred within the first 90 days after the index procedure.
The number of total hospitalizations and the number of
subjects hospitalized in each cohort are detailed in Table 1.
By contrast, freedom from repeat ablation was no longer
statistically significant when repeat ablations that occurred
Figure 2. Survival free from predefined secondary end points, including and excluding events that occurred during the 90-day blanking period
(modified intention-to-treat cohort). A, Freedom from cardiovascular rehospitalization with and without a 90-day blanking period in cryoballoon- vs
radiofrequency current (RFC)–treated cohorts is presented. Freedom from cardiovascular rehospitalization was significantly higher in the
cryoballoon cohort both when events in the blanking period were included in the analysis (log-rank test, P<0.01) and when they were not used (log-
rank test, P=0.02). B, Freedom from repeat ablation in the cryoballoon vs RFC cohort with and without the blanking period is compared. Freedom
from repeat ablation was significantly higher in the cryoballoon cohort when events in the blanking period were included in the analysis (log-rank
test, P=0.03), but the cohorts were no longer statistically different when events in the blanking period were excluded (log-rank test, P=0.10).
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within the 90-day blanking period were removed from the
analysis (P=0.03 versus P=0.10; Figure 2B). The numbers of
repeat ablations in the cryoballoon and RFC cohorts are
presented in Table 2.
With or without the blanking period, the observed differ-
ence in freedom from cardiovascular rehospitalization and
repeat ablation between cohorts continues to diverge beyond
the first year of follow-up (Figure 2). These data may suggest
that, although the timing of initial recurrence was equivalent
between cohorts, the symptoms and severity of recurrence
felt by patients treated with RFC necessitated increased
intervention over time.
What We Can Still Learn: Impact of New
Technology
Over the course of the trial, technological advancements in
both cryoballoon and RFC ablation catheters were introduced
into the commercial market and incorporated into the study at
the discretion of the investigators. In the cryoballoon arm,
Arctic Front ablation catheters were denoted as the first-
generation cryoballoon, and Arctic Front Advance catheters
were labelled as the second-generation cryoballoon. Similarly,
in the RFC arm, ThermoCool and ThermoCool SF were
categorized as the first-generation RFC catheters, whereas
the contact-force sensing ThermoCool SmartTouch catheters
were denoted as the advanced-generation RFC ablation
catheters. New catheter technology was not equally adopted
into the trial; the second-generation cryoballoon was used in
75.6% of patients in the cryoballoon arm, whereas advanced-
generation RFC catheters were used in only 24.7% of patients
in the RFC group.1 The disproportionate use of second-
generation cryoballoon versus advanced-generation RFC
catheters may have obscured the efficacy of the advanced-
generation RFC contact-force sensing technology. Although
there was no difference in the primary efficacy outcome
between catheter generations,1 it is imperative to understand
the influence of newly introduced technology on the compre-
hensive clinical outcomes as new technologies inundate the
field of AF ablation.
Safety and Procedural Outcomes by Catheter
Generation
Additional analyses according to catheter subtype using an
as-treated cohort consistent with prior publications were
performed (Figure 3). Importantly, this revealed no difference in
the primary safety end point between catheter subtypes
(P=0.44; Figure 4). Analyses of procedural data indicated that
total procedure and left atrial dwell times were significantly
shorter for second-generation cryoballoon-treated patients
compared with the first-generation cryoballoon- or any-
generation RFC ablation catheter-treated cohort (P<0.01),
whereas the mean procedure and left atrial dwell times were
unchanged between first- and advanced-generation RFC pro-
cedures (Table 3). Use of the second-generation cryoballoon
reduced the fluoroscopy exposure time compared with patients
treated with the first-generation cryoballoon (2013 versus
2715 minutes). However, the fluoroscopy time for the
second-generation cryoballoon remained higher than for the
first-generation RFC (1719 minutes) or the advanced-gen-
eration RFC (1712 minutes) treated cohorts (Table 3).
The overall rate of acute PVI approached 100% regardless
of the ablation modality used (P=0.13; Table 3). However,
there were catheter-dependent differences in the rate of
acute PVI during treatment of left common pulmonary veins
(LCPVs; P=0.04; Table 3). Specifically, 100% of LCPVs were
isolated with the first-generation (10/10) and second-
generation (16/16) cryoballoon. By contrast, 74.2% (23/31)
of LCPVs were isolated with the first-generation RFC ablation
catheter, which improved to an acute isolation rate of 90.0% (9/
10) with use of the advanced-generation RFC ablation catheter.
Of the 31 LCPVs ultimately treated with RFC, 2 were from
patients initially randomized to cryoballoon ablation (both of
Table 1. Cardiovascular Rehospitalizations Within and
Beyond the Blanking Period by Cohort
Randomization Arm
Time of Cardiovascular
Rehospitalization
No. of
Rehospitalizations
(No. of Subjects; %
of Subjects)
Cryoballoon Total 139 (89; 23.8)
Within blanking period 48 (42; 11.2)
Beyond blanking period 91 (59; 15.8)
Radiofrequency
current
Total 203 (135; 35.9)
Within blanking period 83 (71; 18.9)
Beyond blanking period 120 (86; 22.9)
Table 2. Repeat Ablations Within and Beyond the Blanking
Period by Cohort
Randomization
Arm
Time of the
Repeat Ablation
No. of Repeat
Ablations (No. of
Subjects;
% of Subjects)
Cryoballoon Total 49 (44; 11.8)
Within blanking period 12 (12; 3.2)
Beyond blanking period 37 (34; 9.1)
Radiofrequency
current
Total 70 (66; 17.6)
Within blanking period 19 (19; 5.1)
Beyond blanking period 51 (49; 13.0)
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whom experienced successful acute isolation with the first-
generation RFC ablation catheter). Together, these data
suggest that LCPVs are frequently isolated regardless of the
catheter ablation technology. While RFC ablation catheters are
inherently flexible during lesion application in uncommon
anatomical features, high rates of LCPV isolation via the
cryoballoon are likely enabled by a segmental approach to
circumferential isolation of the LCPV ostium.9
Predefined Secondary Outcomes by Catheter
Subtype
To better understand the influence of the ablation catheter
generation on predefined secondary outcomes, freedom from
cardiovascular rehospitalization and repeat ablation was
analyzed by ablation catheter subtype (Figure 5). This analysis
revealed a significant difference in freedom from cardiovas-
cular rehospitalization between catheter types (P<0.01). Both
first- and second-generation cryoballoon cohorts were asso-
ciated with higher rates of freedom from cardiovascular
rehospitalization compared with either the first- or advanced-
generation RFC cohorts (Figure 5A). Notably, patients treated
with the second-generation cryoballoon experienced a higher
rate of freedom from cardiovascular rehospitalization than
those treated with the first-generation cryoballoon. By
contrast, freedom from cardiovascular rehospitalization was
similar for the first- and advanced-generation RFC catheters
(Figure 5A). Although there was a difference in freedom from
cardiovascular rehospitalization between catheter subtypes,
there was no significant difference in the rates of repeat
ablation between the 4 catheters (Figure 5B).
What We Need to Address in the Future
As with all successful trials, the FIRE AND ICE Trial generated
many questions and future directions for potential clinical
research. Specifically, pressing questions persist in the
categories of repeat ablations, persistent AF, and newer
ablation catheter technologies.
The FIRE AND ICE Redo Study
A substantial proportion of patients experienced recurrence of
AF (37% primary efficacy failure in the FIRE AND ICE Trial)
after an initially successful PVI. In these patients, re-isolation
of the PVs may be warranted. Little is known about redo
ablation after PVI, particularly in regard to electrophysiological
differences after an initial cryoballoon or RFC procedure.
During a follow-up of maximally 33 months, repeat ablations
Figure 3. Flowchart of patient cohort assignment in the FIRE AND ICE Trial. This figure depicts the total number of patients randomized, the
total number of patients in the modified intention-to-treat (ITT) cohort, and the patients who composed the as-treated cohorts used for analyses
of subcatheter differences. Cryo indicates cryoballoon; RFC, radiofrequency current.
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were performed in 12% (n=44) of patients who had undergone
an index PVI with the cryoballoon and 18% (n=66) of patients
after an index PVI using RFC.
Recently, 89 of the 110 FIRE AND ICE Trial patients with
repeat ablations were retrospectively consented and enrolled
in a redo study (ClinicalTrials.gov, identifier NCT03314753)
with the intention to evaluate lesion durability, repeat ablation
strategy, and procedural characteristics in those trial patients.
There were 36 patients originally randomized to cryoballoon
ablation and 53 patients randomized to RFC ablation. These
repeat ablation data are currently being analyzed and will be
published shortly.
Figure 4. Survival free from a primary safety event by catheter subtype. An across-group analysis of the
as-treated cohort revealed there was no statistical difference in the risk of a primary safety event across
catheter subtypes (log-rank test, P=0.44). RFC indicates radiofrequency current.
Table 3. Procedural Data by Catheter Type
Parameter
First-Generation
Cryoballoon (N=90)
Second-Generation
Cryoballoon (N=279)
First-Generation
RFC (N=284)
Advanced-Generation
RFC (N=93) P Value
Acute PVI* 99.2 (351/354) 98.7 (1107/1122) 98.2 (1134/1155) 97.1 (362/373) 0.13†
Acute left common PVI* 100 (10/10) 100 (16/16) 74.2 (23/31)‡ 90.0 (9/10) 0.04†
Procedure time, min 14032 11838 14157 14350 <0.01§
Left atrial dwell time, min 10132 8929 10947 10941 <0.01§
Fluoroscopy time, min 2715 2013 1719 1712 <0.01§
Data are given as meanSD unless otherwise indicated. PVI indicates pulmonary vein isolation; RFC, radiofrequency current.
*Data are given as percentage (number/total). These were treated/targeted pulmonary veins.
†P value from exact test.
‡RF randomization arm treated with ThermoCool: 21/29; cryoballoon randomization arm treated with ThermoCool: 2/2.
§P value from ANOVA.
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Figure 5. Freedom from predefined secondary end points by catheter subtype in the as-treated
cohort.A, Freedom from cardiovascular rehospitalization by catheter subtype is displayed; therewas a
significant difference between catheter types (log-rank test, P<0.01). B, The freedom from repeat
ablation across catheter subtypes in the as-treated cohort. There was no difference in the rate of
repeat ablation when examined by catheter type (log-rank test, P=0.12). RFC indicates radiofrequency
current.
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The FIRE AND ICE II Randomized Trial
AF is progressive in nature, and paroxysmal AF evolves into
persistent AF with an overall rate of 5.5% per year.10 AF can
initiate irreversible fibrosis at many cardiac sites.11 With more
atrial fibrosis, subjects with AF are increasingly likely to
experience less favorable outcomes.12 The clinical implica-
tions of this association warrant further investigation.
There is a need for adequately powered randomized trials
evaluating catheter ablation in subjects with persistent, as
opposed to paroxysmal, AF. The FIRE AND ICE II randomized
outcome trial has been designed to compare the efficacy and
safety of PVI using cryoballoon versus RFC ablation with a
contact-force sensing catheter in subjects with persistent AF.
The primary objective of the trial is to demonstrate that
cryoballoon ablation is noninferior to RFC ablation with
respect to the time-to-first clinical failure, defined as recur-
rence of atrial arrhythmias or intervention for AF (a blanking
period of 90 days will be maintained after the index
procedure), which maintains study design congruence with
historical trials so that the data can be compared. Intervention
for AF will include hospitalizations, cardioversions, repeat
ablations, and new antiarrhythmic subscriptions given for the
treatment of AF. Furthermore, on the basis of magnetic
resonance imaging, the trial will investigate the impact of left
atrial volume and left atrial fibrosis on clinical outcome and
assess lesion formation 3 months after ablation. In addition,
the impact of PVI on electrical sources identified by body
surface mapping will be investigated.
The Potentially Revolutionary Ablation Modality:
Pulsed Electrical Field Ablation
In the next decade, this cryoballoon versus RFC series of trials
may only serve to be a historical reference point as newer or
newly redesigned ablation energies and catheters enter the
commercial market space. The “novel” pulsed electrical field
(PEF) ablation technology13 is (in fact) a revival of an old
technology (namely, electroporation) that was used in the
early days of catheter ablation at different energy settings,
largely with high voltages delivered in a single pulse. PEF
ablation uses similarly high voltages (ie, 900–2500 V), but
they are delivered in multiple ultrarapid millisecond pulses.
The mode of action is unique in that this energy ablates
nonthermally by creating nanoscale pores in cell membranes.
PEF energy is characterized by tissue-specific thresholds,
thereby preferring ablation of myocardial tissue, which has
the lowest threshold for PEF ablation. Therefore, in contrast to
any other energy source, this energy spares collateral
structures, such as the esophagus, arteries, and nerves.
In a small series of 22 patients with AF,13 PEF ablation was
successfully applied to isolate pulmonary veins (100%)
endocardially with a catheter-based approach and to create a
box lesion epicardially during cardiac surgery (86%) with a rather
low number of energy applications (3.30.5 lesions/PV and 2
lesions/patient). No complications were noted. If these initial
results can be verified and reproduced by other independent
investigators, including proof of no or “little” PV reconnection
over time, other available ablation technologies may no longer
need to be refined to improve the results in ablation of AF.
Summary
In 2012, the year the FIRE AND ICE Trial was initiated, the
European Society of Cardiology and the Heart Rhythm Society
consensus statements recognized RFC as the dominant energy
source for AF catheter ablation and discussed PVI as a
promising treatment approach.14,15 In response to the FIRE
AND ICE Trial and many other trials, the consensus documents
were updated to recognize PVI as a safe and effective strategy
for the treatment of AF with either of the 2 leading catheter
ablation modalities, cryoballoon or RFC ablation.16,17 Evalua-
tion of the comprehensive end points, in addition to the primary
end point that demonstrated noninferiority between the
treatment modalities, may have contributed to the acceptance
and adoption of cryoballoon ablation. Indeed, secondary end
points of the trial were critical in identifying clinically important
differences between the 2 treatment cohorts. Thoughtful
design and rigorous assessment of secondary outcomes of
future clinical trials may be essential to defining the patient-
specific impact of new catheter ablation technologies for the
treatment of AF.
Appendix
The FIRE AND ICE Trial Investigators are as follows: Karl-Heinz
Kuck, Andreas Metzner, Feifan Ouyang (Asklepios Klinik St
Georg, Hamburg, Germany); Julian Chun, Alexander F€urnkranz
(Cardioangiologisches Centrum Bethanien, Frankfurt, Ger-
many); Arif Elvan (Isala Klinieken Zwolle, the Netherlands);
Thomas Arentz (Herz-Zentrum Bad Krozingen, Germany);
Michael K€uhne, Christian Sticherling (Universit€atsspital Basel,
Switzerland); Laszlo Geller (Semmelweis Egyetem, Budapest,
Hungary); Matthias Busch (Uniklinik Greifswald, Germany);
Josep Brugada, Lluis Mont (Hospital Clinic de Barcelona,
Spain); Alberto Barrera (Hospital Clınico Universitario “Virgen
de la Victoria” Malaga, Spain); Thomas Deneke (Klinikum Bad
Neustadt, Germany); Jean-Paul Albenque (Clinique Pasteur
Toulouse, France); Volker K€uhlkamp (Herz-Zentrum Bodensee,
Germany); Claudio Tondo (Centro Cardiologico Monzino,
University of Milan, Italy); Ricardo Ruiz-Granell (Hospital
Clinico Universitario Valencia, Spain); Peter Neuzil (NA
Homolce Hospital Prague, Czech Republic); Nicasio Perez-
Castellano (Hospital Clinico San Carlos, Madrid, Spain).
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